Logo

Targeted Genetics Closes $13M Private Placement

Dec 18, 1998
Premium

SEATTLE, Wash.--Targeted Genetics here, a developer of gene and cell therapy products for the treatment of certain acquired and inherited diseases, announced the closing of a $13 million private placement of common stock and warrants with a group of four institutional investors. The investor group, led by GeneChem Technologies Venture Fund, a Canadian-based investment fund, purchased 8.7 million shares of common stock at $1.50 per share. Other new investors were Equitable Life Assurance of the UK, and Societe Financiere d'Innovation of Quebec.

Filed under

Informatics
Breaking News
The Scan

Study Points to Tuberculosis Protection by Gaucher Disease Mutation

A mutation linked to Gaucher disease in the Ashkenazi Jewish population appears to boost Mycobacterium tuberculosis resistance in a zebrafish model of the lysosomal storage condition, a new PNAS study finds.

SpliceVault Portal Provides Look at RNA Splicing Changes Linked to Genetic Variants

The portal, described in Nature Genetics, houses variant-related messenger RNA splicing insights drawn from RNA sequencing data in nearly 335,700 samples — a set known as the 300K-RNA resource.

Automated Sequencing Pipeline Appears to Allow Rapid SARS-CoV-2 Lineage Detection in Nevada Study

Researchers in the Journal of Molecular Diagnostics describe and assess a Clear Labs Dx automated workflow, sequencing, and bioinformatic analysis method for quickly identifying SARS-CoV-2 lineages.

UK Team Presents Genetic, Epigenetic Sequencing Method

Using enzymatic DNA preparation steps, researchers in Nature Biotechnology develop a strategy for sequencing DNA, along with 5-methylcytosine and 5-hydroxymethylcytosine, on existing sequencers.